- Home
- ANIX vs CHCI Comparison
ANIX vs CHCI Comparison
Compare ANIX & CHCI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ANIX
- CHCI
- Stock Information
- Founded
- ANIX 1982
- CHCI 1985
- Country
- ANIX United States
- CHCI United States
- Employees
- ANIX N/A
- CHCI N/A
- Industry
- ANIX Biotechnology: Pharmaceutical Preparations
- CHCI Building operators
- Sector
- ANIX Health Care
- CHCI Real Estate
- Exchange
- ANIX Nasdaq
- CHCI Nasdaq
- Market Cap
- ANIX 91.7M
- CHCI 77.0M
- IPO Year
- ANIX 1987
- CHCI 2004
- Fundamental
- Price
- ANIX $2.59
- CHCI $8.27
- Analyst Decision
- ANIX Strong Buy
- CHCI
- Analyst Count
- ANIX 2
- CHCI 0
- Target Price
- ANIX $8.50
- CHCI N/A
- AVG Volume (30 Days)
- ANIX 101.3K
- CHCI 16.7K
- Earning Date
- ANIX 01-14-2025
- CHCI 12-27-2024
- Dividend Yield
- ANIX N/A
- CHCI N/A
- EPS Growth
- ANIX N/A
- CHCI N/A
- EPS
- ANIX N/A
- CHCI 0.59
- Revenue
- ANIX N/A
- CHCI $45,402,000.00
- Revenue This Year
- ANIX N/A
- CHCI N/A
- Revenue Next Year
- ANIX N/A
- CHCI N/A
- P/E Ratio
- ANIX N/A
- CHCI $13.21
- Revenue Growth
- ANIX N/A
- CHCI 5.57
- 52 Week Low
- ANIX $2.15
- CHCI $4.16
- 52 Week High
- ANIX $5.13
- CHCI $14.48
- Technical
- Relative Strength Index (RSI)
- ANIX 33.20
- CHCI 38.55
- Support Level
- ANIX $2.80
- CHCI $7.63
- Resistance Level
- ANIX $3.43
- CHCI $9.19
- Average True Range (ATR)
- ANIX 0.18
- CHCI 0.53
- MACD
- ANIX -0.04
- CHCI -0.03
- Stochastic Oscillator
- ANIX 11.84
- CHCI 20.99
About ANIX Anixa Biosciences Inc.
Anixa Biosciences Inc, a cancer-focused biotechnology company, developing vaccines and therapies that are focused on critical unmet needs in oncology. The company is developing both diagnostics and therapeutics to detect cancer early, which is curable, and to treat those afflicted once diagnosed. Its segment includes CAR-T Therapeutics; Cancer Vaccines; Anti-Viral Therapeutics and others.
About CHCI Comstock Holding Companies Inc.
Comstock Holding Co Inc is a developer and manager of mixed-use and transit-oriented properties with operations that are majorly focused on the Washington, D.C. metropolitan area. It provides a range of services such as asset management, property management, development and construction management, and other real estate-related services to its asset-owning clients, composed predominantly of institutional real estate investors, high net worth family offices, financial institutions, and governmental bodies seeking to enhance their surrounding communities by developing real estate through public-private partnerships.